Symbiotec Pharmalab Ltd - IPO

Symbiotec Pharmalab Ltd IPO Details

Initial public offering of up to [*] equity shares of face value of Rs.2/- each (equity shares) of the company for cash at a price of Rs.[*] per equity share (including a share premium ofRs.[*] per equity share) (offer price) aggregating up to Rs.2180.00 crores (offer). The offer comprises a fresh issue of up to [*] equity shares of face value of Rs.2/- each aggregating up to Rs.150.00 crores by the company (fresh issue) and an offer for sale of up to [*] equity shares of face value of Rs.2/- each (offered shares) aggregating up to Rs.2030.00 crores, comprising of up to [*] equity shares of face value of Rs.2/- each aggregating up to Rs.180.00 crores by Satwani Holdings LLP (the promoter selling shareholder), up to [*] equity shares of face value of Rs.2/- each aggregating up to Rs.1250.00 crores by Rosewood Investments and up to [*] equity shares of face value of Rs.2/- each aggregating up to Rs.600.00 crores by India Business Excellence fund - III (the investor selling shareholders, and together with the promoter selling shareholder, the selling shareholders and such offer for sale of equity shares by the selling shareholders, the offer for sale). The offer will constitute [*]% of the post-offer paid up equity share capital of the company.In accordance with and subject to regulation 33 of the sebi icdr regulations, the offer may include a reservation of up to [*] equity shares (of face value of Rs.2/- each), aggregating up to Rs.[*] crores (constituting up to 5% of the post offer paid-up equity share capital of the company), for subscription by eligible employees (the employee reservation portion). The offer less the employee reservation portion is hereinafter referred to as the net offer. The offer and the net offer shall constitute [*]% and [*]%, respectively, of the post-offer paid-up equity share capital of the company. The company, in consultation with the book running lead managers, may offer a discount of up to [*]% (equivalent to Rs.[*] per equity share) to the offer price to eligible employees bidding under the employee reservation portion (employee discount).The company, in consultation with the brlms, may consider a further issue of specified securities as may be permitted under applicable law, at its discretion, aggregating up to Rs.30.00 crores (the pre-ipo placement), prior to the filing of the pre-ipo placement, if undertaken, will be at a price to be decided by the company, in consultation with the brlms. If the pre-ipo placement is completed, the amount raised pursuant to the pre-ipo placement will be reduced from the fresh issue, subject to compliance with Rule 19(2)(b) of the securities contracts (regulation) rules, 1957, as amended (scrr). The pre-ipo placement, if undertaken, shall not exceed 20% of the size of the fresh issue. prior to the completion of the offer, the company shall appropriately intimate the subscribers to the pre-ipo placement, prior to allotment pursuant to the preipoplacement, that there is no guarantee that the company may proceed with the offer or that the offer may be successful and will result in the listing of the equity shares on the stock exchanges. Further, relevant disclosures in relation to such intimation to the subscribers to the pre-ipo placement (if undertaken). The face value of the equity share is Rs.2/- each. The offer price is [*] times the face value of the equity shares. The price band, the minimum bid lot and the employee discount, if any,will be decided by the company.

Objective of issue

Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by its Company. General Corporate Purpose.

Symbiotec Pharmalab Ltd Contact Details

Symbiotec Pharmalab Ltd, C-101 247 Park, L B S Marg, Vikhroli West, Mumbai-400083

Phone - 91-22-49186000

Fax - 91-22-49186060

Email - secretarial@symbiotec.com

Website - www.symbiotec.com